The first connectable lateral flow tests at Arab Health 2022

 

Biosynex will present during the show two innovative devices that simplify the diagnosis of SARS-CoV-2: AMPLIQUICK® and LABPAD® Evolution.

 

United Arab Emirates, 17 January 2022 The Biosynex group will be present this year at Arab Health 2022 exhibition. The company, which specializes in the design of medical devices, will present innovative solutions to fight covid-19 epidemic. 

 Biosynex will present during the show two innovative devices that simplify the diagnosis of

SARS-CoV-2: AMPLIQUICK® and LABPAD® Evolution 

The first, BIOSYNEX AMPLIQUICK® enables the detection by RT-PCR of 4 major respiratory viruses. This amplification kit eliminates the extraction step, thus reducing the number of handling operations and saving laboratory technicians valuable time. The AMPLIQUICK® device also enabled the detection of one of the first cases of the OMICRON variant in mainland France.  

Thierry Paper, Managing Director stated: “BIOSYNEX has invested heavily in the development of reliable and easy-to-use RT-PCR test solutions. The detection of a first case of the Omicron variant with our kit confirms the quality of our solutions and is a real source of satisfaction for the team. We are currently working to extend our range of molecular biology to support laboratories in their efforts to manage the Covid-19 pandemic. 

 

 

Share
Tweet